ENMD-2076   Click here for help

GtoPdb Ligand ID: 7885

Synonyms: ENMD 2076 | ENMD2076
PDB Ligand
Compound class: Synthetic organic
Comment: ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor. It inhibits a distinct profile of angiogenic tyrosine kinases in addition to the Aurora A kinase. These angiogenic targets include VEGFR, Flt3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 72.97
Molecular weight 375.22
XLogP 4
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C
Isomeric SMILES CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C
InChI InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
InChI Key BLQYVHBZHAISJM-CMDGGOBGSA-N
No information available.
Summary of Clinical Use Click here for help
ENMD-2076 progressed to Phase 2 clinical evaluation for indications including ovarian clear cell cancers (NCT01914510), advanced/metastatic soft tissue sarcoma (NCT01719744) and advanced fibrolamellar carcinoma (NCT02234986). Development does not appear to have progressed further.